Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573621 | 0.97 | FKBP1A (0.68) | POLBFKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL25592921 | 0.92 | CYP3A4 (0.66) | POLBFKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL25592977 | 0.90 | MEN1 (0.65) | POLBFKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3577905 | 0.85 | P2RX7 (0.55) | POLBFKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3681344 | 0.85 | POLB (0.58) | POLBFKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3576076 | 0.82 | KMT2A (0.48) | POLBFKBP1AALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL3577733 | 0.82 | USP2 (0.49) | POLBFKBP1AALDH1A1MEN1KMT2A | |
| SCHEMBL3567863 | 0.82 | KMT2A (0.48) | POLBFKBP1AALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5737566 | 0.82 | P2RX7 (0.55) | POLBFKBP1AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8088647 | 0.81 | POLB (0.60) | POLBFKBP1AALDH1A1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | POLB 4716/4885FKBP1A 2112/4885ALDH1A1 4057/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | POLB 4716/4885FKBP1A 2112/4885ALDH1A1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.